2 Kids Suffering From Rare Disease Approved For Treatment - FOX 35 News Orlando

2 Kids Suffering From Rare Disease Admitted Into Gene Therapy Study

Posted: Updated:

Two kids who suffer from a rare disease that attacks the brain, nerves and muscles have been admitted into a gene therapy study that was considered to be their best hope.

FOX 29 introduced you to seven-year-old Eli and four-year-old Ella in October. The two, who are from the same family, were diagnosed with Metachromatic Leukodystrophy, also known as MLD.

A gene therapy study in Milan, Italy was their best chance.

On Friday, FOX 29 learned the two were admitted into the study. The family tells us their treatment is scheduled to begin in May.

  • Local NewsMore>>

  • Police: Man Left Child In Car While Gambling In Del.

    Police: Man Left Child In Car While Gambling In Del.

    Delaware State Police have arrested a Maryland man for leaving his child unattended in a car while he was gambling in a casino.
    Delaware State Police have arrested a Maryland man for leaving his child unattended in a car while he was gambling in a casino.
  • New Jersey OKs Trump Plaza shutdown Sept. 16

    New Jersey OKs Trump Plaza shutdown Sept. 16

    New Jersey casino regulators have given final approval to Trump Plaza's plan to shut down in two weeks.
    New Jersey casino regulators have given final approval to Trump Plaza's plan to shut down in two weeks.
  • Friends work to 'save' Pennsylvania bucket bear

    Friends work to 'save' Pennsylvania bucket bear

    A group of friends has tracked down and helped to save a western Pennsylvania bear that got its head stuck in a bucket-like contraption.
    A group of friends has tracked down and helped to save a western Pennsylvania bear that got its head stuck in a bucket-like contraption.
Powered by WorldNow

35 Skyline Drive
Lake Mary, FL 32746

Phone: (407) 644-3535
News Tips: (866) 55-FOX35

Didn't find what you were looking for?
All content © Copyright 2000 - 2014 Fox Television Stations, Inc. and Worldnow. All Rights Reserved.
Privacy Policy | New Terms of Service What's new | Ad Choices